The Interfaith Alliance for Safer Communities Hosted A Roundtable Event - Covid-19: Faith as a Moral Framework for our Communities
7.9.2020 16:00:00 EEST | Business Wire | Press release
The Interfaith Alliance for Safer Communities (IAFSC), an NGO established to empower faith leaders to work for the safety and security of communities, has held a successful online interfaith roundtable event with representation from 50 participants representing 7 faiths from 18 countries.
Speaking about the event, Dr. Vinu Aram (Director of Shanti Ashram and Co-Moderator of Religions for Peace) said, “I want to thank the Interfaith Alliance for Safer Communities for this meeting today. The work of the Interfaith Alliance is so important: in the disruption of the ways we worked together as communities during Covid-19, we have found that children have become more vulnerable... While every nation is trying to find its own solution, those of us who work with children have to be greater advocates for their cause.”
Chief Executive of the IAFSC, Dana Humaid, said “Faith has rarely been more important or powerful than in the current crisis. The IAFSC hosted this event in order to allow discussion and facilitate knowledge-sharing from different religions and communities on a global scale. Faith leaders have the power to assist their communities, to be advocates for those in need, to make a difference and offer comfort and also to try and reduce the suffering of people under their watch.”
The ongoing Covid-19 pandemic has been unprecedented in modern times, and has had a significant impact on the physical, mental and spiritual wellbeing of our communities. Millions have lost their jobs and are facing struggles such as hunger and homelessness. This pandemic has had unforeseen consequences as well, such as a surge in the cases of child sexual abuse as well as an increase in hate crimes based on race and religion.
Key Outcomes
The roundtable discussions aimed to address the most significant problems being faced by our communities today.
Supporting those most impacted by coronavirus in rebuilding their lives
- We are all impacted by this pandemic, we are not all affected the same way.
- The role of faith and faith leaders is to build, promote and invigorate a spirit of resilience.
- When faith leaders aren’t able to contact their community and provide them with help or assistance in a difficult time, it is a challenge for everyone in the community.
- Faith leaders have been taking on the bulk of the work in some communities.
- We need to be careful of our blind spots, we cannot create a situation in which we overlook other communities that now need our help, such as those that may not be considered traditionally vulnerable sectors of society.
Protecting the digital dignity of children and supporting the victims and their families
- Faith leaders can be champions in leading the prevention of sexual exploitation.
- It is important to base our responses on data and evidence and go from there.
- No one is an expert in the prevention of exploitation. Community is key.
- We need to increase budgets for social and health services.
- Family and family stability are also vital.
- Education, mobilization, support and universal healthcare are all necessary in improving our communities.
Among others, organisations represented included: Arigatou International, ECPAT International, New York Board of Rabbis, Conference of European Rabbis, Bahá'í International Community, Peres Center for Peace and Innovation, Shanti Ashram, World Economic Forum, UNICEF, Conference of European Churches, Markaz Knowledge City (India), and Online Anti-Semitism Task Force.
Visit https://iafsc.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200907005253/en/
Contact information
For more information:
Caroline Sullivan
media@iasfc.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
